Reply to letter: Retrospective cost-effectiveness of the 23-valent pneumococcal polysaccharide vaccination program in Australia.

A T Newall J G Wood C Chen P McIntyre P Beutels

Vaccine

School of Public Health and Community Medicine, UNSW Australia, Sydney, NSW, Australia; Centre for Health Economics Research and Modelling Infectious Diseases (CHERM ID), Vaccine and Infectious Disease Institute, University of Antwerp, Antwerp, Belgium.

Published: December 2019

Download full-text PDF	Source
http://dx.doi.org/10.1016/j.vaccine.2019.09.108	DOI Listing

Publication Analysis

Top Keywords

reply letter

letter retrospective

retrospective cost-effectiveness

cost-effectiveness 23-valent

23-valent pneumococcal

pneumococcal polysaccharide

polysaccharide vaccination

vaccination program

program australia

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!